Titlebook: Choriocarcinoma; Transactions of a Co James F. Holland (Chief of Medicine A and Director Conference proceedings 1967 Springer-Verlag Berlin

憤慨點吧

RECUR

Transplantation Immunity and the Trophoblast,ns are exchanged between members of an out-bred population. The cellular isoantigens responsible for inciting a host to respond against a homograft — the . — are usually referred to as .. These antigens are determined by co-dominant . and vary considerably in their relative strengths or sensitizing

ABIDE

詞匯

很像弓]

ESPY

Early Development of Choriocarcinoma,e I. The patient material is received from all parts of the United States but not all material is sent to the Registry. None has been sent on the basis of the age of the patient. In all probability this sampled data of age distribution is valid for all patients with trophoblastic disease in the Unit

vibrant

The Mechanism of Action of Folic Acid Antagonists,nificant regression of a neoplasm, acute lymphocytic leukemia in children (.., 1948). Nearly ten years ago, in October 1955, methotrexate was first demonstrated to possess activity which has subsequently proved curative in a majority of trophoblastic neoplasms (.., 1956).

CRAMP

On the Prevention and Treatment of Choriocarcinoma,e difficulty was in considering these entities as three separate and distinct conditions rather than accepting them as stages in the progression from a benign state, hydatidiform mole, to a highly malignant phase, choriocarcinoma. All these stages may be present in one patient at the same time. The

orient

Chemotherapeutic Prophylaxis Against the Development of Choriocarcinoma Following the Removal of Hyfty-three patients were treated with Amethopterin, usually 10 mg daily for 5–10 days. In 10 of these patients, Amethopterin was also instilled into the uterine cavity along with the systemic therapy. Thirty-nine patients were treated with other drugs: Nitrogen mustard N-oxide, thio-TEPA, Cyclophosph

interlude

The Effect of Methotrexate in Trophoblastic Diseases,re treated with methotrexate at a dose of 17.5–25 mg/daily for 2 to 5 days in repeat courses. One patient who was previously treated by hysterectomy for choriocarcinoma had no evidence of active growth at the onset of chemotherapy, but subsequently died. The remaining ten patients all had disseminat